Clinical and translational allergy
Short-Course Subcutaneous Immunotherapy With Mannan-Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements
Par Raskopf E, Passamera S, Klimek L et 12 autres.
Contenu en anglais
Résumé
Background
The mannan-conjugated birch pollen polymerised allergoid EP-088_T502 has previously been shown to reduce allergic symptoms and anti-allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP-088_T502 administered as eight subcutaneous injections over six pre-seasonal treatment visits.